Search

Author/Creator Min, C.-K.

1. P942: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA. (23rd June 2022)

Authors:
Usmani, S. Z.; Mielnik, M.; Koh, Y.; Alonso Alonso, A.; Leleu, X.; Quach, H.; Min, C.-K.; Janowski, W.; Abdallah, A.-O.; Garg, M.; Sandhu, I.; Ocio San Miguel, E. M.; Oriol, A.; Rodriquez-Otero, P.; Ramasamy, K.; Weisel, K.; Besemer, B.; Cavo, M.; Zhou, X. L.; Kaisermann, M. C.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
832
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. P975: INTERIM ANALYSIS OF PHASE II STUDY OF DARATUMUMAB IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA WHO RECEIVED 1 PRIOR LINE OF THERAPY (KMM1906). (23rd June 2022)

Authors:
Yoo, K. H.; Gang, G. W.; Yi, J. H.; Kim, M. K.; Kim, H. J.; Kim, S.-H.; Park, J. S.; Lee, J.-J.; Min, C.-K.; Lee, J. H.; Cho, D.; Kim, K.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
865
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. P939: SYNERGISTIC EFFECTS OF LOW DOSE BELANTAMAB MAFODOTIN IN COMBINATION WITH A GAMMA-SECRETASE INHIBITOR (NIROGACESTAT) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-5 STUDY. (23rd June 2022)

Authors:
Nooka, A.; Lonial, S.; Grosicki, S.; Hus, M.; Song, K.; Facon, T.; Callander, N. S.; Ribrag, V.; Uttervall, K.; Quach, H.; Vorobyev, V.; Min, C.-K.; Cheng, S.; Smith, L. M.; Yu, J.; Collingwood, T.; Holkova, B.; Kremer, B. E.; Gupta, I. V.; Richardson, P. G.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
829
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search